Korea Research Institute of Bioscience and Biotechnology

A&rt Co., Ltd.

Soon Sil Hyun

Young Woo Park

Ki Won Jo

Ji Hyun Park

Seok Ho Yoo

Jae Eun Park

Myeoung Hee Jang

Hye Nan Kim

Kyu Won Cho

Yun Jung Park

Chan Woong Park

Sun Jeong Jo

The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of SEQ ID NO. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition. The present invention shows the effects of suppressing metastasis, infiltration, angiogenesis, and growth of cancer by specifically inhibiting c-Met endocytosis and effectively inhibiting HGF/c-Met signaling pathway associated with metastasis and growth of various types of cancer cells. Therefore, the present invention can be applied to an anticancer agent for various types of cancer.

Pharmaceutical composition containing an endocytic motif and protein transduction domains for preventing or treating cancer

The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual.

Drug conjugate comprising drug linked to human c-Met antibody, and use therefor

Growing community of inventors

Daejeon, South Korea

Soon Sil Hyun